Macrolides

Azithromycin belongs to a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria. Antibiotics like azithromycin do not work against colds, influenza, or other viral infections.

It is used to treat certain bacterial infections such as pneumonia (a lung infection), bronchitis (an infection of the airways leading to the lungs), and infections of the ears, sinuses, skin, and throat. Maver Laboratory

Therapeutic Indications Clarithromycin - Oral, in normal-release and modified-release forms: Adults and children ≥12 years: pharyngitis, tonsillitis, sinusitis (diagnosed), acute bronchitis, acute exacerbation of chronic bronchitis, bacterial pneumonia (community-acquired), mild-to-moderate skin and soft tissue infections, folliculitis, cellulitis, erysipelas. - Oral, in normal-release forms: Adults and children ≥12 years: localized or disseminated M. avium or M. intracellulare infection, localized M. chelonae, M. fortuitum, and M. kansaii infection, gastric or duodenal ulcer associated with H. pylori (with an appropriate antiulcer agent). Prevention of disseminated M. avium complex infection in high-risk HIV patients (CD4 lymphocytes ≤ 50/mm 3 ). Children > 12 months to 11 years: streptococcal pharyngitis, bacterial bronchitis and pneumonia, acute otitis media, impetigo, folliculitis, cellulitis, abscesses. - IV: Adv.: Parenteral treatment for streptococcal pharyngitis or tonsillitis if first-line treatment with beta-lactams is not possible or there is demonstrated sensitivity to S. pyogenes; diagnosed acute bacterial sinusitis; acute exacerbation of chronic bronchitis; mild-moderate skin and soft tissue infections if beta-lactams are not appropriate. It is a macrolide antibiotic with bactericidal action and is effective against a wide range of aerobic and anaerobic bacteria, as well as gram-positive and gram-negative bacteria. It is used for upper and lower respiratory tract infections, skin and soft tissue infections, and infections caused by the Mycobacterium complex (M.

Clarithromycin is useful for the treatment of: Upper respiratory tract infections (tonsillitis, pharyngitis, sinusitis, otitis). Lower respiratory tract infections (bronchitis, pneumonia). Therapeutic indications for Clarithromycin: - Oral, in immediate-release and modified-release formulations: Adults and children ≥12 years: pharyngitis, tonsillitis, sinusitis (diagnosed), acute bronchitis, acute exacerbation of chronic bronchitis, bacterial pneumonia (community-acquired), mild-to-moderate skin and soft tissue infections, folliculitis, cellulitis, erysipelas. - Oral, in immediate-release formulations: Adults and children ≥12 years: localized or disseminated infection caused by M. avium or M. intracellulare, localized infection caused by M. chelonae, M. fortuitum, and M. kansaii. Gastric or duodenal ulcer associated with H. pylori (in conjunction with appropriate anti-ulcer medication). Prevention of disseminated M. avium complex infection in high-risk HIV patients (CD4 lymphocytes ≤ 50/mm³). Children > 12 months to 11 years: streptococcal pharyngitis, bacterial bronchitis and pneumonia, acute otitis media, impetigo, folliculitis, cellulitis, abscesses. - IV: Adults: parenteral treatment of streptococcal pharyngitis or tonsillitis if first-line treatment with beta-lactams is not possible or there is demonstrated susceptibility to S. pyogenes; diagnosed acute bacterial sinusitis; acute exacerbation of chronic bronchitis; mild-to-moderate skin and soft tissue infections if beta-lactams are not appropriate.

Therapeutic Indications Clarithromycin - Oral, in immediate-release and modified-release formulations: adults and children ≥12 years: pharyngitis, tonsillitis, sinusitis (diagnosed), acute bronchitis, acute exacerbation of chronic bronchitis, bacterial pneumonia (community-acquired), mild-to-moderate skin and soft tissue infections, folliculitis, cellulitis, erysipelas. - Oral, in immediate-release formulations: adults and children ≥12 years: localized or disseminated infection caused by M. avium or M. intracellulare, localized infection caused by M. chelonae, M. fortuitum, and M. kansaii. Gastric or duodenal ulcer associated with H. pylori (in conjunction with an appropriate anti-ulcer agent). Prevention of disseminated M. avium complex infection in high-risk HIV-positive patients (CD4 lymphocytes ≤ 50/mm³). Children > 12 months to 11 years: streptococcal pharyngitis, bacterial bronchitis and pneumonia, acute otitis media, impetigo, folliculitis, cellulitis, abscesses. - IV: Adults: parenteral treatment of streptococcal pharyngitis or tonsillitis if first-line treatment with beta-lactams is not possible or there is demonstrated susceptibility to S. pyogenes; diagnosed acute bacterial sinusitis; acute exacerbation of chronic bronchitis; mild-to-moderate skin and soft tissue infections if beta-lactams are not appropriate.